Skip to search formSkip to main contentSkip to account menu

IPI-145

Known as: PI3K delta/gamma Inhibitor IPI-145 
An orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

IsoquinolinesPurines
NCIt Antineoplastic Agent Terminology

Narrower (1)

duvelisib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.
Duvelisib (IPI-145) is an oral inhibitor of phosphatidylinositol 3-kinase (PI3K)-δ/γ isoforms currently in clinical development… 
Highly Cited
2017
Highly Cited
2017
Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ.
Checkpoint inhibitors are relatively inefficacious in head and neck cancers, despite an abundance of genetic alterations and a T… 
Review
2015
Review
2015
PI3K inhibitors in inflammation, autoimmunity and cancer
Highly Cited
2015
Highly Cited
2015
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL
The functional relevance of the B-cell receptor (BCR) and the evolution of protein kinases as therapeutic targets have recently… 
Highly Cited
2015
Highly Cited
2015
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
Purpose: Bruton's tyrosine kinase (BTK) is a critical enzyme in the B-cell receptor pathway and is inhibited by ibrutinib due to… 
Highly Cited
2014
Highly Cited
2014
Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Introduction: Signaling via PI3K-δ and PI3K-γ has distinct and complimentary effects on malignant B-cells and nonmalignant immune… 
Highly Cited
2014
Highly Cited
2014
IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.
Chronic lymphocytic leukemia (CLL) displays constitutive phosphatidylinositol 3-kinase (PI3K) activation resulting from aberrant… 
Highly Cited
2014
Highly Cited
2014
a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL
Introduction: Signaling via PI3K-δ and PI3K-γ is essential for both normal and malignant B-cell and T-cell proliferation… 
Highly Cited
2013
Highly Cited
2013
PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.
Review
2012
Review
2012
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.
Activation of PI3K (phosphoinositide 3-kinase) is a shared response to engagement of diverse types of transmembrane receptors… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)